The University of Chicago Header Logo

Connection

Christopher Shea to Melanoma

This is a "connection" page, showing publications Christopher Shea has written about Melanoma.
Connection Strength

4.236
  1. Update on Thin Melanoma: Outcome of an International Workshop. Adv Anat Pathol. 2016 Jan; 23(1):24-9.
    View in: PubMed
    Score: 0.403
  2. Melanocytic tumors with intraepidermal melanophages: a report of five cases with review of 231 archived cutaneous melanocytic tumors. J Cutan Pathol. 2015 Jun; 42(6):394-9.
    View in: PubMed
    Score: 0.382
  3. Melanocytes, melanocyte stem cells, and melanoma stem cells. Clin Dermatol. 2013 Mar-Apr; 31(2):166-78.
    View in: PubMed
    Score: 0.331
  4. The recurrent nevus phenomenon: a history of challenge, controversy, and discovery. Arch Pathol Lab Med. 2011 Jul; 135(7):842-6.
    View in: PubMed
    Score: 0.295
  5. Immunohistochemistry of melanocytic proliferations. Arch Pathol Lab Med. 2011 Jul; 135(7):853-9.
    View in: PubMed
    Score: 0.295
  6. Are en face frozen sections accurate for diagnosing margin status in melanocytic lesions? Am J Clin Pathol. 2003 Aug; 120(2):203-8.
    View in: PubMed
    Score: 0.170
  7. CD34 expression in desmoplastic melanoma. J Cutan Pathol. 2001 Nov; 28(10):508-12.
    View in: PubMed
    Score: 0.151
  8. Maturing papillomatous nevoid melanoma in the scalp mimicking recurrent melanocytic nevus: A case report of previously undescribed subtype of nevoid melanoma. Pathol Int. 2022 Jan; 72(1):59-64.
    View in: PubMed
    Score: 0.150
  9. Primary chondroid melanoma. J Cutan Pathol. 2001 Oct; 28(9):482-5.
    View in: PubMed
    Score: 0.150
  10. Malignant melanoma with paradoxical maturation. Am J Surg Pathol. 2000 Dec; 24(12):1600-14.
    View in: PubMed
    Score: 0.142
  11. Up-Regulation of PARP1 Expression Significantly Correlated with Poor Survival in Mucosal Melanomas. Cells. 2020 05 05; 9(5).
    View in: PubMed
    Score: 0.136
  12. Recent developments in the pathology of melanocytic neoplasia. Dermatol Clin. 1999 Jul; 17(3):615-30, ix.
    View in: PubMed
    Score: 0.128
  13. Prognostic role of tumoral PDL1 expression and peritumoral FoxP3+ lymphocytes in vulvar melanomas. Hum Pathol. 2018 03; 73:176-183.
    View in: PubMed
    Score: 0.116
  14. KIT mutations and CD117 overexpression are markers of better progression-free survival in vulvar melanomas. Br J Dermatol. 2017 Nov; 177(5):1376-1384.
    View in: PubMed
    Score: 0.114
  15. Genotypic and Phenotypic Features of BAP1 Cancer Syndrome: A Report of 8 New Families and Review of Cases in the Literature. JAMA Dermatol. 2017 10 01; 153(10):999-1006.
    View in: PubMed
    Score: 0.114
  16. Scaly erythematous lesion in a patient with extensive solar damage. Malignant melanoma in situ, amelanotic type. Arch Dermatol. 1996 Oct; 132(10):1239, 1242.
    View in: PubMed
    Score: 0.106
  17. Evaluation of the Melanocytic Pathology Assessment Tool and Hierarchy for Diagnosis (MPATH-Dx) classification scheme for diagnosis of cutaneous melanocytic neoplasms: Results from the International Melanoma Pathology Study Group. J Am Acad Dermatol. 2016 Aug; 75(2):356-63.
    View in: PubMed
    Score: 0.103
  18. Clinical validation of a gene expression signature that differentiates benign nevi from malignant melanoma. J Cutan Pathol. 2015 Apr; 42(4):244-52.
    View in: PubMed
    Score: 0.096
  19. Angiotropic metastatic malignant melanoma. Am J Dermatopathol. 1995 Feb; 17(1):58-62.
    View in: PubMed
    Score: 0.095
  20. Nevus versus melanoma: to FISH, or not to FISH. Adv Anat Pathol. 2011 May; 18(3):229-34.
    View in: PubMed
    Score: 0.073
  21. Granulomatous eruption after BCG vaccine immunotherapy for malignant melanoma. J Am Acad Dermatol. 1989 Nov; 21(5 Pt 2):1119-22.
    View in: PubMed
    Score: 0.066
  22. Use of immunohistochemistry in melanocytic lesions. J Cutan Pathol. 2008 Nov; 35 Suppl 2:1-10.
    View in: PubMed
    Score: 0.061
  23. PAX3 expression in primary melanomas and nevi. Mod Pathol. 2008 May; 21(5):525-30.
    View in: PubMed
    Score: 0.059
  24. Atypical cellular blue nevi (cellular blue nevi with atypical features): lack of consensus for diagnosis and distinction from cellular blue nevi and malignant melanoma ("malignant blue nevus"). Am J Surg Pathol. 2008 Jan; 32(1):36-44.
    View in: PubMed
    Score: 0.058
  25. Dysplastic naevi with moderate to severe histological dysplasia: a risk factor for melanoma. Br J Dermatol. 2006 Nov; 155(5):988-93.
    View in: PubMed
    Score: 0.053
  26. Angiotropism in epidermotropic metastatic melanoma: another clue to the diagnosis. Am J Dermatopathol. 2006 Oct; 28(5):429-33.
    View in: PubMed
    Score: 0.053
  27. Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901. J Immunother. 2006 Jan-Feb; 29(1):95-101.
    View in: PubMed
    Score: 0.050
  28. Pagetoid melanocytosis: when is it significant? Pathology. 2004 Oct; 36(5):435-44.
    View in: PubMed
    Score: 0.046
  29. Histological characteristics of metastasizing thin melanomas: a case-control study of 43 cases. Arch Dermatol. 2002 May; 138(5):603-8.
    View in: PubMed
    Score: 0.039
  30. Desmoplastic (sclerotic) nevus: an underrecognized entity that resembles dermatofibroma and desmoplastic melanoma. Am J Surg Pathol. 1999 Jul; 23(7):786-94.
    View in: PubMed
    Score: 0.032
  31. Primary malignant melanoma of the esophagus. J Surg Oncol. 1997 Nov; 66(3):201-6.
    View in: PubMed
    Score: 0.029
  32. Immunohistochemical expression of retinoblastoma protein in cutaneous melanomas. Br J Dermatol. 1995 Dec; 133(6):890-5.
    View in: PubMed
    Score: 0.025
  33. p53 expression is rare in cutaneous melanomas. Am J Dermatopathol. 1995 Aug; 17(4):344-9.
    View in: PubMed
    Score: 0.024
  34. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. Cancer Res. 1995 Jul 01; 55(13):2713-8.
    View in: PubMed
    Score: 0.024
  35. Immunohistochemical expression of BCL-2 in melanomas and intradermal nevi. J Cutan Pathol. 1994 Oct; 21(5):393-7.
    View in: PubMed
    Score: 0.023
  36. Mutation and expression of the p53 gene in human malignant melanoma. Melanoma Res. 1994 Feb; 4(1):35-45.
    View in: PubMed
    Score: 0.022
  37. Oncogenes in melanomas. J Dermatol. 1992 Nov; 19(11):853-67.
    View in: PubMed
    Score: 0.020
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.